Tumor-to-tumor intracranial metastasis is an uncommon phenomenon, and metastasis to pituitary adenoma is extremely rare.1 Contrary to adenomas, which are the most frequent neoplastic lesions of the pituitary gland, and metastases to a normal pituitary gland, which account for 2% of all pituitary lesions, only about 35 cases of metastases to pituitary adenoma have been described.2 The most frequently reported malignancies that metastasize to pituitary adenomas are lung, renal, and breast cancers.1,2 The prognosis for metastases to pituitary adenoma is poor due to the presence of advanced neoplastic disease.3
A 61-year-old woman was admitted to the department of neurosurgery due to hormonally nonfunctioning sellar mass, causing severe visual impairment and headaches over 2 to 3 months. The patient had been treated for 8 months for breast cancer with metastatic spread to bones and liver. She was treated with HER2-targeting monoclonal antibodies (pertuzumab and trastuzumab) in combination with docetaxel, and palliatively irradiated due to L4 vertebral body metastatic tumor. Magnetic resonance imaging (MRI) of the head, performed due to neurological symptoms, revealed a sellar mass with a significant suprasellar extension (Figure 1A). The tumor was larger compared with the previous image (6 months earlier), which was interpreted as asymptomatic pituitary macroadenoma (1.8 × 2 × 2.1 cm). Although the MRI results were consistent with the diagnosis of the pituitary macroadenoma, some intratumor lower signal intensity could suggest a collision tumor. The neurological examination revealed bitemporal visual field defects, while the hormonal profile showed only mild hyperprolactinemia (67 ng/ml; reference range, 3–23 ng/ml) and somatotropic insufficiency (insulin-like growth factor-1, 43 ng/ml; reference range, 58–170 ng/ml for women older than 60 years of age). The patient underwent endoscopic transsphenoidal removal of the lesion. The histopathological and immunohistochemical examination of the surgical specimen evidenced 2 distinct components: metastatic breast adenocarcinoma and oncocytic gonadotroph pituitary adenoma (Figure 1B–1G). The MIB-1 proliferation index was significantly different for both tumors (<1% adenoma vs >50% metastatic carcinoma). Metastatic tumor cells were positive for cytokeratin 7 and human epidermal growth factor receptor 2, and negative for progesterone receptors, p40 antigen, and thyroid transcription factor 1 (Figure 1C–1G). Immunostaining for follicle stimulating hormone and steroidogenic factor 1 in adenoma cells confirmed the diagnosis of gonadotroph pituitary tumor (Figure 1E and 1G). Electron microscopy revealed different ultrastructural features of both tumor components including cancer cells and pituitary adenoma (Figure 1H). After the surgery, the visual impairment and severe headaches resolved, the hormonal profile showed partial hypopituitarism (Supplementary material, Table S1). The patient underwent stereotactic radiation therapy for the sellar area (20 Gy). Over 1-year of postoperative follow-up showed no recurrence of the neoplastic process of both pituitary tumors. The relatively long survival time is unusual for similar cases.1,2
The symptoms and imaging features of pituitary adenoma metastases are similar to those of pituitary adenoma tumors, with headaches and visual deterioration being the most commonly reported.1,3 For symptomatic cases, the treatment of choice is surgery, in order to decompress the optic chiasm and collect the tumor tissue for histopathological diagnosis.4
In patients with systemic neoplastic disease and previously diagnosed pituitary adenoma, the metastatic spread to the primary pituitary tumor should be included in the differential diagnosis. The histopathological analysis is crucial to demonstrate the 2 histologically distinct tumor components.
Natalia Rzewuska, MS, Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, ul. W.K. Roentgena 5, 02-781 Warszawa, Poland, phone: +48 22 546 29 59, email: natalia.rzewuska@pib-nio.pl
May 17, 2021.
June 27, 2021.
July 2, 2021.
None declared.
Kunicki J, Rzewuska N, Maksymowicz M, et al. Metastasis of breast adenocarcinoma to pituitary adenoma. Pol Arch Intern Med. 2021; 131: 16052. doi:10.20452/pamw.16052
- 1.
- Hoellig A, Niehusmann P, Flacke S, Kristof RA. Metastasis to pituitary adenoma: case report and review of the literature. Cent Eur Neurosurg. 2009; 70: 149-153.Crossref
- 2.
- Helton M, Abu-Rmaileh M, Thomas K, et al. Pituitary metastatic composite tumors: a case report with next-generation sequencing and review of the literature. Case Rep Oncol Med. 2020; 2020: 5073236.Crossref
- 3.
- Bret P, Jouvet A, Madarassy G, et al. Visceral cancer metastasis to pituitary adenoma: report of two cases. Surgl Neurol. 2001; 55: 284-290.Crossref
- 4.
- Donofrio CA, Pizzimenti C, Djoukhadar I, et al. Colorectal carcinoma to pituitary tumour: tumour to tumour metastasis. Br J Neurosurg. 2020 Sep 21. [Epub ahead of print].Crossref